• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Genetron Holdings Limited

    3/29/24 6:02:34 AM ET
    $GTH
    Medical Specialities
    Health Care
    Get the next $GTH alert in real time by email
    S-8 POS 1 tm2331317-8_s8pos.htm S-8 POS

     

    As filed with the United States Securities and Exchange Commission on March 29, 2024 

    Registration No. 333-252371 

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

     

     

    POST-EFFECTIVE AMENDMENT NO. 1 

    TO 

    FORM S-8

     

     

     

    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

     

     

     

    Genetron Holdings Limited

     

    (Exact name of registrant as specified in its charter)

     

     

     

    Cayman Islands   N/A
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)
     

    1-2/F, Building 11, Zone 1,

    No.8 Life Science Parkway

    Changping District, Beijing, 102206

    People’s Republic of China

    +86 10 5090-7500

     

    (Address, including zip code, of Principal Executive Offices)

     

     

     

     

    2019 Genetron Health Share Incentive Plan

    2019 Genetron Health Share Incentive Scheme

     

    (Full title of the plans)

     

     

     
           
     

    Cogency Global Inc.

    122 East 42nd Street, 18th Floor

    New York, NY 10168

    (800) 221-0102

     

    (Name, address and telephone number, including area code, of agent for service)

     

     

     

    Copies to:

     

    Li He, Esq.

    Xuelin (Steve) Wang, Esq.

    Davis Polk & Wardwell LLP

    18/F, The Hong Kong

    Club Building 3A Chater Road,

    Central Hong Kong,

    People’s Republic of China

    +852 2533 3300

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

     

    Large accelerated filer ¨   Accelerated filer x
    Non-accelerated filer ¨   Smaller reporting company  ¨
        Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ¨

     

     

     

     

     

     

     

     

    DEREGISTRATION OF SECURITIES

     

    This Post-Effective Amendment No. 1 (this “Post-Effective Amendment”) relates to the registration statement on Form S-8 (File No. 333-252371) (the “Registration Statement”), which was filed with the Securities and Exchange Commission on January 25, 2021 by Genetron Holdings Limited, a company established under the laws of the Cayman Islands (the “Company”). Under the Registration Statement, a total of 54,791,600 ordinary shares, par value US$0.00002 per share, of the Company, were registered for issuance under the Company’s 2019 Genetron Health Share Incentive Plan and 2019 Genetron Health Share Incentive Scheme (collectively, the “Plans”). This Post-Effective Amendment is being filed for the sole purpose of deregistering any unissued shares previously registered under the Registration Statement and issuable under the Plans.

     

    On March 28, 2024, pursuant to the agreement and plan of merger dated October 11, 2023 (the “Merger Agreement”) among the Company, New Genetron Holding Limited (“Parent”) and Genetron New Co Limited (“Merger Sub”), Merger Sub was merged with and into the Company, with the Company being the surviving company resulting from the merger and becoming a wholly owned subsidiary of Parent (the “Merger”). Upon completion of the Merger, the Company became a privately-held company.

     

    As a result of the Merger, the Company has terminated all the offerings of its securities pursuant to the Registration Statement. The Company hereby removes from registration, by means of this Post-Effective Amendment, any and all of the securities registered under the Registration Statement which remain unsold as of the date of this Post-Effective Amendment.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Beijing, the People’s Republic of China, on March 29, 2024.

     

      GENETRON HOLDINGS LIMITED
         
      By:

    /s/ Sizhen Wang

        Name:  Sizhen Wang
        Title: Chief Executive Officer

     

    No other person is required to sign this Post-Effective Amendment to the Registration Statement in reliance upon Rule 478 of the Securities Act of 1933, as amended.

     

     

     

    Get the next $GTH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GTH
    SEC Filings

    View All

    SEC Form 15-12G filed by Genetron Holdings Limited

    15-12G - Genetron Holdings Ltd (0001782594) (Filer)

    4/8/24 6:04:10 AM ET
    $GTH
    Medical Specialities
    Health Care

    SEC Form S-8 POS filed by Genetron Holdings Limited

    S-8 POS - Genetron Holdings Ltd (0001782594) (Filer)

    3/29/24 6:02:34 AM ET
    $GTH
    Medical Specialities
    Health Care

    SEC Form 25-NSE filed by Genetron Holdings Limited

    25-NSE - Genetron Holdings Ltd (0001782594) (Subject)

    3/28/24 4:24:30 PM ET
    $GTH
    Medical Specialities
    Health Care

    $GTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genetron Health Announces Completion of Going Private Transaction

    BEIJING, March 28, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today the completion of its merger (the "Merger") with Genetron New Co Limited ("Merger Sub"), pursuant to the previously announced agreement and plan of merger, dated as of October 11, 2023 (the "Merger Agreement"), among the Company, New Genetron Holding Limited ("Parent") and Merger Sub. As a result of the Merger, the Company has become a wholly owned subsidiary of Parent and wil

    3/28/24 1:30:11 PM ET
    $GTH
    Medical Specialities
    Health Care

    Genetron Health Announces Shareholders' Approval of Merger Agreement

    BEIJING, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that at an extraordinary general meeting of shareholders (the "EGM") held today, the Company's shareholders voted in favor of, among other things, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of October 11, 2023 (the "Merger Agreement"), among the Company, New Genetron Holding Limited ("Parent") and Genetron New Co Limite

    2/21/24 6:00:00 AM ET
    $GTH
    Medical Specialities
    Health Care

    Genetron Health to Hold Extraordinary General Meeting of Shareholders

    BEIJING, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has called an extraordinary general meeting of shareholders (the "EGM"), to be held at on February 21, 2024 at 9:00 a.m. (Beijing time) at 1/F, Building 11, Zone 1, No. 8 Life Science Parkway, Changping District, Beijing, People's Republic of China, to consider and vote on, among other matters, the proposal to authorize and approve the previously announced agreement and

    1/17/24 6:05:00 AM ET
    $GTH
    Medical Specialities
    Health Care

    $GTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)

    SC 13D/A - Genetron Holdings Ltd (0001782594) (Subject)

    4/2/24 5:44:00 PM ET
    $GTH
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)

    SC 13D/A - Genetron Holdings Ltd (0001782594) (Subject)

    4/1/24 4:15:35 PM ET
    $GTH
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)

    SC 13D/A - Genetron Holdings Ltd (0001782594) (Subject)

    3/29/24 8:04:05 AM ET
    $GTH
    Medical Specialities
    Health Care

    $GTH
    Leadership Updates

    Live Leadership Updates

    View All

    Genetron Health Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee

    BEIJING, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that the special committee (the "Special Committee") of the Company's Board of Directors (the "Board") has retained Kroll, LLC (operating through its Duff & Phelps Opinions Practice) as its independent financial advisor and Davis Polk & Wardwell LLP as its independent legal counsel. The Special Committee was formed to evaluate and consider the previously announced preliminary

    9/2/22 7:00:00 AM ET
    $GTH
    Medical Specialities
    Health Care

    TellBio Unveils Next-Generation Liquid Biopsy Platform Focused on Early Detection and Treatment of Cancer

    --Closes $5 million Series A financing-- --Appoints Pritesh J. Gandhi, PharmD, as Chief Executive Officer and Annie Partisano, PharmD, MS, as Senior Vice President and Head of Operations-- --Announces exclusive license of TellDx platform to Genetron Holdings Limited for China-- --Secures Deployment of TellDx at ARUP Laboratories, Inc-- BEVERLY, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- TellBio, Inc., a development stage biotechnology company focused on revolutionizing the detection and treatment of cancer through its unique and proprietary circulating tumor cell (CTC) technology, TellDx, and complementary therapeutics platform, TellRx, today announced the closing of a $5 million Series A

    5/10/21 7:00:00 AM ET
    $GTH
    Medical Specialities
    Health Care

    $GTH
    Financials

    Live finance-specific insights

    View All

    Genetron Health Reports Unaudited First Quarter 2022 Financial Results

    BEIJING, June 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its unaudited financial results for the first quarter ended March 31, 2022. First Quarter and Recent Highlights Recorded total revenue of RMB 110.3 million (US $17.4 million) in the first quarter of 2022, representing 19.8% increase over the same period in 2021. LDT revenue was RMB 81.5 million (US $12.9 million), representing 13.5% increase over the same period in 2021.IVD re

    6/2/22 7:19:58 AM ET
    $GTH
    Medical Specialities
    Health Care

    Genetron Health to Announce First Quarter 2022 Unaudited Financial Results and Host Investor Call on June 2, 2022

    BEIJING, May 23, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the first quarter ended March 31, 2022 on June 2, 2022 before the US market open. Management will host a conference call for investors at 8:30 a.m. ET (8:30 p.m. Beijing time) on Thursday, June 2, 2022. The conference call can be accessed by dialing the following numbers: United States:+1-833-239-5565China Domestic:400-820-528

    5/23/22 4:05:00 PM ET
    $GTH
    Medical Specialities
    Health Care

    Genetron Health Announces Unaudited Fourth Quarter and Full Year 2021 Financial Results

    BEIJING, March 29, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced its unaudited preliminary financial results for the fourth quarter and full year ended December 31, 2021. 2021 and Recent Business Highlights Therapy Selection: As of December 31, 2021, the Company had 58 hospital partners, of which 30 were IVD hospital partners. Genetron Health is continuing to enhance its in-hospital sales effort.

    3/29/22 7:26:05 AM ET
    $GTH
    Medical Specialities
    Health Care